<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01896050</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 2009.029</org_study_id>
    <nct_id>NCT01896050</nct_id>
  </id_info>
  <brief_title>Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer</brief_title>
  <acronym>LOGRIBMET</acronym>
  <official_title>A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Third-generation Aromatase Inhibitors and Tamoxifen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early stage hormone receptor positive breast cancer is typically treated with adjuvant
      endocrine therapy in order to decrease risk of breast cancer recurrence and to improve
      overall survival from the disease. Typical agents used for treatment include tamoxifen and
      the aromatase inhibitors. In postmenopausal women, aromatase inhibitor therapy is
      increasingly common because it is associated with fewer long-term serious toxicities compared
      to tamoxifen. However, aromatase inhibitors cause arthralgias in 40-50% of patients, which
      can influence adherence to therapy and can lead to treatment discontinuation in a minority of
      cases. The mechanism underlying development of this toxicity remains unclear, and predictors
      of who will develop these symptoms remain undefined. Initial reports suggest that grip
      strength decreases during aromatase inhibitor therapy, and that body-mass index may influence
      development of this symptom. Therefore, this longitudinal study has been developed to
      determine change in grip strength over time in women treated with aromatase inhibitors and
      tamoxifen, as well as to identify potential associations between change in grip strength and
      BMI. Patient self-reported symptoms will also be collected. A total of 115 women with early
      stage breast cancer who are initiating therapy with either an aromatase inhibitor or
      tamoxifen will be enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Change in Body Mass Index on Change in Grip Strength With Aromatase Inhibitor Therapy</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>Change in BMI between baseline and 12 months of endocrine therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Medication on Change in Grip Strength</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>Effect of either aromatase inhibitor or tamoxifen therapy on change in grip strength between baseline and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association Between Baseline Body Mass Index and Discontinuation of Aromatase Inhibitor Therapy Within the First 12 Months</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>Associations between baseline BMI and whether or not aromatase inhibitor-treated patients discontinued treatment by 12 months. In the original statistical analysis plan, it was only intended to examine the association with aromatase inhibitor-treated patients, and not tamoxifen-treated patients. The numbers below reflect the number of patients in each group who discontinued initial endocrine therapy within the first 12 months of treatment</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">115</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Arthralgia</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>AI therapy</arm_group_label>
    <description>Subjects who started treatment with any of the three aromatase inhibitor (AI) medications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamoxifen</arm_group_label>
    <description>Subjects who started treatment with tamoxifen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrozole, letrozole, exemestane</intervention_name>
    <description>Patients were treated with one of the listed anti-hormonal medications for up to one year</description>
    <arm_group_label>AI therapy</arm_group_label>
    <other_name>Arimidex, Femara, Aromasin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>Patients were treated with tamoxifen for up to one year</description>
    <arm_group_label>Tamoxifen</arm_group_label>
    <other_name>Novaldex</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood is being collected at baseline for DNA extraction. Serum is being collected at
      baseline and after 3, 6, and 12 months.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Postmenopausal women with hormone receptor positive breast cancer who are initiating
        therapy with either an aromatase inhibitor or tamoxifen.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage 0-III breast cancer who are scheduled to receive endocrine therapy with
             tamoxifen or an aromatase inhibitor

          -  All prior surgery and chemotherapy should be complete

          -  Age 18 and above and postmenopausal

        Exclusion Criteria:

          -  Major rheumatologic disorders

          -  Concomitant sex hormone containing drugs or Leutinizing Hormone Releasing Hormone
             agonist therapy

          -  For those subjects initiating treatment with an aromatase inhibitor, prior tamoxifen
             within 4 weeks of enrollment

          -  For those subjects initiating treatment with tamoxifen, prior aromatase inhibitor
             within 4 weeks of enrollment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norah L Henry, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2013</study_first_submitted>
  <study_first_submitted_qc>July 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <results_first_submitted>March 3, 2016</results_first_submitted>
  <results_first_submitted_qc>April 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 12, 2016</results_first_posted>
  <last_update_submitted>May 25, 2016</last_update_submitted>
  <last_update_submitted_qc>May 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan Cancer Center</investigator_affiliation>
    <investigator_full_name>Lynn Henry</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Joint pain</keyword>
  <keyword>Grip strength</keyword>
  <keyword>Hormone receptor positive breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Arthralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AI Therapy</title>
          <description>Subjects who started treatment with any of the three aromatase inhibitor (AI) medications</description>
        </group>
        <group group_id="P2">
          <title>Tamoxifen</title>
          <description>Subjects who started treatment with tamoxifen</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55">This includes only patients who remained on the same aromatase inhibitor medication for 12 months</participants>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AI Therapy</title>
          <description>Subjects who started treatment with any of the three aromatase inhibitor (AI) medications</description>
        </group>
        <group group_id="B2">
          <title>Tamoxifen</title>
          <description>Subjects who started treatment with tamoxifen</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="93"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="115"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="41" upper_limit="79"/>
                    <measurement group_id="B2" value="61.5" lower_limit="44" upper_limit="69"/>
                    <measurement group_id="B3" value="62" lower_limit="41" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body-mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.4" spread="7.1"/>
                    <measurement group_id="B2" value="29" spread="7"/>
                    <measurement group_id="B3" value="30.1" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist-hip ratio</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.91" spread="0.09"/>
                    <measurement group_id="B2" value="0.92" spread="0.12"/>
                    <measurement group_id="B3" value="0.91" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximum grip strength, right hand</title>
          <units>kPa</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="11.7"/>
                    <measurement group_id="B2" value="56.4" spread="10.9"/>
                    <measurement group_id="B3" value="57.3" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximum grip strength, left hand</title>
          <units>kPa</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.8" spread="10.9"/>
                    <measurement group_id="B2" value="53.7" spread="10.7"/>
                    <measurement group_id="B3" value="54.6" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Average pain</title>
          <description>Patients reported pain on a 0-10 visual analog scale, with 0 being no pain and 10 being worst pain imaginable.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.3" spread="2.1"/>
                    <measurement group_id="B2" value="2.4" spread="1.9"/>
                    <measurement group_id="B3" value="2.3" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Change in Body Mass Index on Change in Grip Strength With Aromatase Inhibitor Therapy</title>
        <description>Change in BMI between baseline and 12 months of endocrine therapy</description>
        <time_frame>baseline and 12 months</time_frame>
        <population>These data only include patients who completed a full 12 months of treatment with either an aromatase inhibitor or tamoxifen and had grip strength data at both baseline and 12 months. Patients could have switched from one aromatase inhibitor to another. Those patients who discontinued treatment prior to the 12 month period were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>AI Therapy</title>
            <description>Subjects who started treatment with any of the three aromatase inhibitor (AI) medications</description>
          </group>
          <group group_id="O2">
            <title>Tamoxifen</title>
            <description>Subjects who started treatment with tamoxifen</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Change in Body Mass Index on Change in Grip Strength With Aromatase Inhibitor Therapy</title>
          <description>Change in BMI between baseline and 12 months of endocrine therapy</description>
          <population>These data only include patients who completed a full 12 months of treatment with either an aromatase inhibitor or tamoxifen and had grip strength data at both baseline and 12 months. Patients could have switched from one aromatase inhibitor to another. Those patients who discontinued treatment prior to the 12 month period were excluded.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="5.70"/>
                    <measurement group_id="O2" value="2.44" spread="6.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Compare difference in change in body mass index between baseline and 12 months between aromatase inhibitor- and tamoxifen-treated patients</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Examine association between change in body mass index and change in grip strength with aromatase inhibitor therapy. For the primary outcome, linear regression was used for analysis with change of grip strength as response variable. In the original statistical analysis plan only aromatase inhibitor-treated patients were to be included in this analysis. This analysis was not performed on the tamoxifen group because it isn't clinically relevant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4262</p_value>
            <method>Regression, Linear</method>
            <param_type>BMI squared</param_type>
            <param_value>-0.01845</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02308</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Medication on Change in Grip Strength</title>
        <description>Effect of either aromatase inhibitor or tamoxifen therapy on change in grip strength between baseline and 12 months</description>
        <time_frame>baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AI Therapy</title>
            <description>Subjects who started treatment with any of the three aromatase inhibitor (AI) medications</description>
          </group>
          <group group_id="O2">
            <title>Tamoxifen</title>
            <description>Subjects who started treatment with tamoxifen</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Medication on Change in Grip Strength</title>
          <description>Effect of either aromatase inhibitor or tamoxifen therapy on change in grip strength between baseline and 12 months</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="15.9"/>
                    <measurement group_id="O2" value="0.6" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of change in maximum grip strength between baseline and 12 months for aromatase inhibitor-treated versus tamoxifen-treated patients</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association Between Baseline Body Mass Index and Discontinuation of Aromatase Inhibitor Therapy Within the First 12 Months</title>
        <description>Associations between baseline BMI and whether or not aromatase inhibitor-treated patients discontinued treatment by 12 months. In the original statistical analysis plan, it was only intended to examine the association with aromatase inhibitor-treated patients, and not tamoxifen-treated patients. The numbers below reflect the number of patients in each group who discontinued initial endocrine therapy within the first 12 months of treatment</description>
        <time_frame>baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aromatase Inhibitor</title>
            <description>Aromatase inhibitor-treated patients</description>
          </group>
          <group group_id="O2">
            <title>Tamoxifen</title>
            <description>Tamoxifen-treated patients</description>
          </group>
        </group_list>
        <measure>
          <title>Association Between Baseline Body Mass Index and Discontinuation of Aromatase Inhibitor Therapy Within the First 12 Months</title>
          <description>Associations between baseline BMI and whether or not aromatase inhibitor-treated patients discontinued treatment by 12 months. In the original statistical analysis plan, it was only intended to examine the association with aromatase inhibitor-treated patients, and not tamoxifen-treated patients. The numbers below reflect the number of patients in each group who discontinued initial endocrine therapy within the first 12 months of treatment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Association between baseline body mass index and discontinuation of aromatase inhibitor therapy. The original statistical analysis plan only called for analyzing the aromatase inhibitor-treated patients, not the tamoxifen-treated patients.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>only unexpected serious adverse events were collected</desc>
      <group_list>
        <group group_id="E1">
          <title>AI Therapy</title>
          <description>Subjects who started treatment with any of the three aromatase inhibitor (AI) medications</description>
        </group>
        <group group_id="E2">
          <title>Tamoxifen</title>
          <description>Subjects who started treatment with tamoxifen</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>one patient died during study participation of reasons unrelated to study participation or AI therapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>symptom leading to treatment discontinuation</sub_title>
                <description>For expected toxicities, we only collected information about whether a patient felt her symptoms were bothersome enough to stop treatment, not treatment about the individual symptoms.</description>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="93"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Norah Lynn Henry, MD</name_or_title>
      <organization>University of Michigan Comprehensive Cancer Center</organization>
      <phone>734-936-4991</phone>
      <email>norahh@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

